A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m² and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma

Pritesh PatelDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA; Correspondence[email protected]

Annie L. OhDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA;

Matthew KoshyUniversity of Illinois Cancer Center, Chicago, IL, USA; ;Department of Radiation Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL, USA;

Karen SweissUniversity of Illinois Cancer Center, Chicago, IL, USA; ;Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA;

Santosh L. SarafDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

John G. QuigleyDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

Irum KhanDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

Nadim MahmudDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

Eileen HackerUniversity of Illinois Cancer Center, Chicago, IL, USA; ;Department of Biobehavioural Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, USA

Howard OzerDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

David J. PeaceDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

Ralph R. WeichselbaumDepartment of Radiation Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL, USA;

Bulent AydoganDepartment of Radiation Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL, USA;

Damiano RondelliDivision of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA; ;University of Illinois Cancer Center, Chicago, IL, USA;

show all

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m² and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m² and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma